Analystreport

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) had its price target raised by analysts at Chardan Capital from $25.00 to $34.00. They now have a "buy" rating on the s

Dicerna Pharmaceuticals, Inc.  (DRNA) 
Last dicerna pharmaceuticals, inc. earnings: 2/27 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.dicerna.com